Vibrotactile stimulation for treating moderate Parkinson's disease
Patterned Multichannel Vibrotactile Stimulation for the Longitudinal Treatment of Moderate Stage Parkinson's Disease
NA · Synergic Medical Technologies, Inc. · NCT05830110
This study is testing a new type of gentle vibration therapy to see if it can help people with moderate Parkinson's disease feel better by easing their motor symptoms.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 45 Years to 90 Years |
| Sex | All |
| Sponsor | Synergic Medical Technologies, Inc. (industry) |
| Locations | 1 site (Eugene, Oregon) |
| Trial ID | NCT05830110 on ClinicalTrials.gov |
What this trial studies
This research examines the effectiveness of a non-invasive vibrotactile stimulation protocol, known as coordinated reset (CR), aimed at alleviating motor symptoms in patients with moderate stage Parkinson's disease. The study will enroll up to thirty adults who will alternate between active and sham therapy every two months, serving as their own control. Participants will undergo daily four-hour vibrotactile stimulation sessions at home, with the option to break them into two blocks for convenience. The longitudinal nature of the study allows for continued treatment for motivated participants, with monitoring of medication usage and device effectiveness.
Who should consider this trial
Good fit: Ideal candidates are adults aged 45 to 90 with a diagnosis of bilateral, moderate stage idiopathic Parkinson's disease.
Not a fit: Patients on dopamine agonist medications exhibiting compulsive behaviors may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a non-invasive treatment option that alleviates motor symptoms in Parkinson's disease patients.
How similar studies have performed: While the approach is innovative, similar studies using non-invasive stimulation techniques have shown promise in treating motor symptoms in neurological conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * between the ages 45 and 90 * diagnosis of bilateral, moderate stage idiopathic PD * qualify for EEG procedures Exclusion Criteria: * on dopamine agonist medications and exhibiting compulsive behaviors
Where this trial is running
Eugene, Oregon
- Synergic Medical Technologies — Eugene, Oregon, United States (RECRUITING)
Study contacts
- Principal investigator: Phan Luu, PhD — Synergic Medical Technologies, Inc.
- Study coordinator: Elyria Kabasenche, BS
- Email: elyria.kabasenche@synergicmed.com
- Phone: 541-510-7068
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Parkinson's Disease, vibrotactile